Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters

Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters

Probiotic supplements containing high β-galactosidase-producing bacteria may aid in the management of lactose intolerance. We previously isolated a strain of Bifidobacterium adolescentis, iVS-1, from the fecal sample of a human donor after consumption of galactooligosaccharides (GOS), a prebiotic de...

Full description

Saved in:
Bibliographic Details
Main Authors: Monica Ramakrishnan, Tzu-Wen L. Cross, Anna Clapp Organski, Sindusha Mysore Saiprasad, Abigayle M. R. Simpson, Daniel J. Tancredi, Mallory J. Van Haute, Chloe M. Christensen, Zachery T. Lewis, Thomas A. Auchtung, Jens Walter, Robert Hutkins, Dennis A. Savaiano
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Gut Microbes Reports
Subjects:
Bifidobacteria
Bifidobacterium adolescentis
galactooligosaccharides
lactose digestion
lactose intolerance
gut microbiome
Online Access:https://www.tandfonline.com/doi/10.1080/29933935.2025.2508199
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Probiotic supplements containing high β-galactosidase-producing bacteria may aid in the management of lactose intolerance. We previously isolated a strain of Bifidobacterium adolescentis, iVS-1, from the fecal sample of a human donor after consumption of galactooligosaccharides (GOS), a prebiotic derived from lactose. Therefore, it was hypothesized that iVS-1 might reduce symptoms associated with lactose maldigestion. Compared to other probiotic strains, iVS-1 had high β-galactosidase activity and reduced gas formation by fecal communities during in vitro fermentations of lactose or milk. A randomized placebo-controlled clinical trial was then conducted with 21 lactose maldigesters, randomized to receive either B. adolescentis iVS-1 (n = 11) or placebo (n = 10) daily for 2 weeks. Compared to the two-week run-in period, iVS-1 abundance was higher both at the end of the treatment period (p = 0.0005) and after the 2-week post-treatment period (p = 0.045). The iVS-1 group reported less overall daily symptoms during the treatment period when compared to placebo (p = 0.032) and had significant improvement for fecal urgency (p = 0.033) and diarrhea (p = 0.006). The metabolism of lactose, reduction of gas, and improvement of multiple gastrointestinal symptoms suggest that B. adolescentis iVS-1 may be an effective treatment for lactose intolerance.Trial Registration: The trial is registered at ClinicalTrials.gov (https://clinicaltrials.gov/study/NCT05668468).
ISSN:2993-3935

Similar Items